Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dioxidin vs Miramistin in superficial pyoderma
NCT05561816Phase 3Completed
- Sponsor
- Valenta Pharm
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dioxidine in Superficial Pyoderma (2 arms), sponsored by Valenta Pharm. Primary endpoint: Proportion of patients who experienced complete cure of the disease at Day 10. Started Jul 2022; status: completed.
02
Drugs
dioxidine
03
Conditions
Superficial Pyoderma
Beyond the preview
Go deeper on NCT05561816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561816.